Article
Immunology
Linyang Gan, Huan Chen, Xiaowei Liu, Li Zhang
Summary: This study investigated the incidence of immune-related adverse events (irAEs) of immune checkpoint inhibitor therapy and reported the clinical features, management, and outcomes of ophthalmic irAEs. Medical records of 962 patients who received ICI therapy were retrospectively reviewed, and 248 patients (25.8%) experienced irAEs. The first-year incidences of total irAEs and ophthalmic irAEs were 23.5% and 1.1% respectively. The most common ICI received was pembrolizumab (38.8%).
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Katrin Madjar, Rajat Mohindra, Gonzalo Duran-Pacheco, Rashad Rasul, Laurent Essioux, Vidya Maiya, G. Scott Chandler
Summary: A post-hoc meta-analysis using data from 15 Roche sponsored clinical trials with atezolizumab revealed baseline risk factors associated with the onset of immune-related adverse events (irAEs). The study aims to optimize the benefit/risk balance in patients receiving cancer immunotherapy.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Mizuho Asada, Takahisa Mikami, Takahiro Niimura, Yoshito Zamami, Yoshihiro Uesawa, Masayuki Chuma, Keisuke Ishizawa
Summary: This study utilized the FAERS database to evaluate the risk factors for ICI-related pneumonitis, showing a significantly higher reporting rate of pneumonitis among ICI users and a strong association with age, especially in those under 60 years old. This suggests that certain populations, including younger age and ICI users, may have an increased risk of ICI-related pneumonitis and require close monitoring.
Review
Oncology
Xiao-Tong Zhang, Nan Ge, Zi-Jian Xiang, Tao Liu
Summary: This study evaluated the incidence of cardiotoxicity related to immune checkpoint inhibitor (ICI) therapies for lung cancer. The results showed that single ICI did not increase the risk of cardiotoxicity compared to chemotherapy, while single ICI plus chemotherapy increased the risk of cardiotoxicity by 67% compared to chemotherapy alone. Combination immunotherapy did not increase the risk of cardiotoxicity compared to single ICI.
CANCER CELL INTERNATIONAL
(2022)
Article
Pharmacology & Pharmacy
Cong Wang, Jinyi Lin, Yan Wang, David H. Hsi, Jiahui Chen, Tianshu Liu, Yuhong Zhou, Zhenggang Ren, Zhaochong Zeng, Leilei Cheng, Junbo Ge
Summary: By conducting a retrospective analysis of ICI-associated myocarditis, we identified two subgroups based on corticosteroid responsiveness: corticosteroid-sensitive and corticosteroid-resistant. Corticosteroid-resistant patients require larger doses and longer duration of corticosteroid treatment, with a higher mortality rate. The use of tofacitinib in corticosteroid-resistant patients may offer a new therapeutic option for ICI-associated myocarditis.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Immunology
Naoki Hamada, Ayaka Maeda, Kaoru Takase-Minegishi, Yohei Kirino, Yumiko Sugiyama, Ho Namkoong, Nobuyuki Horita, Ryusuke Yoshimi, Hideaki Nakajima
Summary: Immune checkpoint inhibitor (ICI)-related myositis is a rare and potentially fatal condition with a low incidence rate and diverse clinical features, emphasizing the importance of early recognition and intervention. The development of myositis induced by ICI, particularly PD-1 inhibitors, is associated with a higher risk of concomitant myocarditis, highlighting the need for close monitoring and appropriate treatment strategies.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Chuan Zhang, Zhulu Chen, Shu Qin, Yuxi Zhu, Linjie Shu, Zhong Zuo
Summary: This study investigated the incidence and risk factors of immune checkpoint inhibitors (ICI)-related adverse cardiovascular events (ACEs) and left ventricular dysfunction (LVD) caused by ICI. The results showed that patients treated with ICI may develop multiple ACEs, including acute myocarditis, pericarditis, ECG abnormalities, and elevated cardiac biomarkers. The incidence of LVD is high after ICI treatment, and echocardiography is helpful for early detection. Hypertension or poor LV systolic or diastolic function at baseline are predictors of LVD after ICI treatment.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Jason Kuniyoshi, Ricky Huang, Horyun Choi, Monika Bernas, Witina Techasatian, Yoshito Nishimura
Summary: ICIs have revolutionized cancer treatment by targeting molecules to activate T-cells and show curative responses for patients with metastatic melanoma, non-small cell lung cancer, head and neck, and renal cancers. However, the occurrence of life-threatening immune-related adverse events should be taken into consideration.
CANADIAN JOURNAL OF CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Valentina A. A. Rossi, Joanna Gawinecka, Florentia Dimitriou, Arnold von Eckardstein, Reinhard Dummer, Frank Ruschitzka, Christian M. M. Matter
Summary: A 54-year old patient with metastatic melanoma developed asymptomatic myositis and myocarditis after combined immune checkpoint inhibitors therapy. The diagnosis was based on the typical time window after therapy, recurrence upon re-challenge, elevated CK, high-sensitive troponin T and I, mild NT-proBNP increase, and positive magnetic resonance imaging criteria. Notably, high-sensitive troponin I showed a faster increase and fall and greater heart-specificity compared to troponin T in the context of ICI-related myocarditis. The patient had to discontinue ICI therapy and switch to a less effective systemic treatment. This case report underscores the differential value of high-sensitive troponin T and I for diagnosing and monitoring ICI-related myositis and myocarditis.
Review
Biochemistry & Molecular Biology
Angela Cozma, Nicolae Dan Sporis, Andrada Luciana Lazar, Andrei Buruiana, Andreea Maria Ganea, Toma Vlad Malinescu, Bianca Mihaela Berechet, Adriana Fodor, Adela Viviana Sitar-Taut, Vasile Calin Vlad, Vasile Negrean, Olga Hilda Orasan
Summary: Immune checkpoint inhibitors (ICIs) are a significant advancement in cancer treatment, but they can cause adverse cardiac effects, especially myocarditis. Understanding and researching these cardiac effects are crucial for treating cancer patients receiving ICIs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Immunology
Qian Xing, Zhongwei Zhang, Biao Zhu, Qionghua Lin, Lihua Shen, Fangfang Li, Zhili Xia, Zhiyong Zhao
Summary: This article reports a case of immune-related myocarditis in a patient with stage IV nasopharyngeal carcinoma during immune checkpoint inhibitor therapy. Tofacitinib, targeting the Janus kinase-signal transducer and activator of transcription signal pathway, was successfully used in the treatment of steroid-refractory immune-related myocarditis. The patient showed improvement without major adverse cardiac events.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Li Zeng, Gang Ma, Kai Chen, Qiao Zhou
Summary: This study examined the trend of ICIs-associated rheumatic irAEs using bibliometric methods, finding that the United States is the leading contributor and observing shifts in research focus through keyword analysis and citation bursts.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Anesthesiology
Adrienne K. Ho, Anthony M-H Ho, Tim Cooksley, Giang Nguyen, Jason Erb, Glenio B. Mizubuti
Summary: Immune checkpoint inhibitors are a new treatment modality for cancer that can restore antitumor immunity by blocking the binding of cancer cell proteins to T-cell checkpoints. However, they may also lead to immune-related adverse events, including autoimmune complications.
ANESTHESIA AND ANALGESIA
(2021)
Article
Oncology
Lee S. Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, Baptiste Abbar, Bruno Pinna, Yves Allenbach, Jean-Paul Mira, Javid Moslehi, Michelle Rosenzwajg, Joe-Elie Salem
Summary: This article describes a case in which nearly lethal immune-checkpoint inhibitor (ICI)-induced myocarditis was reversed by the treatment of abatacept with adjusted dosage. This provides a basis for personalized treatment of patients with severe ICI adverse events.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Oncology
Stephane Ederhy, Joe-Elie Salem, Laurent Dercle, Abrar Saqif Hasan, Marion Chauvet-Droit, Pascal Nhan, Samy Ammari, Bruno Pinna, Alban Redheuil, Samia Boussouar, Stephane Champiat, Laurie Soulat-Dufour, Ariel Cohen
Summary: Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment, but also come with a spectrum of immune-related toxicities, including cardiovascular toxicities. ICI-related myocarditis has a high fatality rate, posing challenges in diagnosis and management.
FRONTIERS IN ONCOLOGY
(2021)
Article
Chemistry, Medicinal
Rie Ando-Matsuoka, Kenta Yagi, Mayu Takaoka, Yuko Sakajiri, Tomokazu Shibata, Ryusuke Sawada, Akinori Maruo, Koji Miyata, Fuka Aizawa, Hirofumi Hamano, Takahiro Niimura, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Satoshi Sakaguchi, Yoshito Zamami, Yoshihiro Yamanishi, Keisuke Ishizawa
Summary: This study investigated the effects of vonoprazan, a novel gastric acid secretion inhibitor, on VEGF secretion in cancer cells and proposed it as an alternative to PPIs for cancer chemotherapy. The results showed that vonoprazan did not increase VEGF expression in cancer cells, suggesting that it may not interfere with the therapeutic effects of anti-VEGF cancer chemotherapy.
DRUG DEVELOPMENT RESEARCH
(2023)
Article
Pharmacology & Pharmacy
Takahiro Niimura, Yoshito Zamami, Koji Miyata, Takahisa Mikami, Mizuho Asada, Keijo Fukushima, Masaki Yoshino, Satoru Mitsuboshi, Naoto Okada, Hirofumi Hamano, Takumi Sakurada, Rie Matsuoka-Ando, Fuka Aizawa, Kenta Yagi, Mitsuhiro Goda, Masayuki Chuma, Toshihiro Koyama, Yuki Izawa-Ishizawa, Hiroaki Yanagawa, Hiromichi Fujino, Yoshihiro Yamanishi, Keisuke Ishizawa
Summary: Myasthenia gravis (MG) can be caused by immune checkpoint inhibitors (ICIs), with different patient characteristics compared to idiopathic MG. Analysis of reports from the US FDA Adverse Event Reporting System revealed that MG was more frequently reported in patients using ICIs. Logistic regression analysis showed no significant difference in reporting rate between men and women, but it was higher in older individuals.
JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Cell Biology
Jun Matsumoto, Anzu Nishimoto, Shogo Watari, Hideo Ueki, Shoya Shiromizu, Naohiro Iwata, Tatsuaki Takeda, Soichiro Ushio, Makoto Kajizono, Masachika Fujiyoshi, Toshihiro Koyama, Motoo Araki, Koichiro Wada, Yoshito Zamami, Yasutomo Nasu, Noritaka Ariyoshi
Summary: This study found that the mRNA expression levels of UGT genes are downregulated in renal cell carcinoma (RCC) tissues and that the UGT2B7-161C > T variant and high UGT2B7 mRNA expression are correlated with better cancer-specific survival and overall survival in patients with RCC.
MOLECULAR AND CELLULAR BIOCHEMISTRY
(2023)
Article
Public, Environmental & Occupational Health
Yuki Otsuka, Hideharu Hagiya, Shinnosuke Fukushima, Ko Harada, Toshihiro Koyama, Fumio Otsuka
Summary: The worldwide spread of tick-borne diseases is a concern for public health. This study focused on clarifying the trends in the incidence of Japanese spotted fever (JSF), one of Japan's most prevalent tick-borne diseases. The findings showed that the incidence of JSF has been increasing over the past two decades, especially in eastern Japan and among the older population.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
(2023)
Article
Pharmacology & Pharmacy
Satoru Mitsuboshi, Hirofumi Hamano, Yurika Kuniki, Takahiro Niimura, Masayuki Chuma, Soichiro Ushio, Tsung-Jen Lin, Jun Matsumoto, Tatsuaki Takeda, Makoto Kajizono, Yoshito Zamami, Keisuke Ishizawa
Summary: This study analyzed data from the MDV database in Japan and the FAERS to investigate the association between PPI use and rhabdomyolysis risk. Both databases consistently showed a significant association between PPI use and increased risk of rhabdomyolysis.
ANNALS OF PHARMACOTHERAPY
(2023)
Article
Public, Environmental & Occupational Health
Takahiro Niimura, Koji Miyata, Hirofumi Hamano, Yuuki Nounin, Hiroto Unten, Masaki Yoshino, Satoru Mitsuboshi, Fuka Aizawa, Kenta Yagi, Toshihiro Koyama, Mitsuhiro Goda, Yasunari Kanda, Yuki Izawa-Ishizawa, Yoshito Zamami, Keisuke Ishizawa
Summary: Recently, cases of cardiovascular toxicities caused by anaplastic lymphoma kinase (ALK) inhibitors, specifically pericarditis, have been reported. However, the prevalence of these adverse events among all ALK inhibitors remains unclear. This study analyzed data from VigiBase to evaluate the cardiovascular toxicity profile of different ALK inhibitors. The results showed differences in cardiotoxicity profiles among the ALK inhibitors, with all five inhibitors associated with pericarditis signals.
Article
Oncology
Satoru Mitsuboshi, Hirofumi Hamano, Takahiro Niimura, Aya F. Ozaki, Pranav M. Patel, Tsung-Jen Lin, Yuta Tanaka, Ikuya Kimura, Naohiro Iwata, Shoya Shiromizu, Masayuki Chuma, Toshihiro Koyama, Yoshihiro Yamanishi, Yasunari Kanda, Keisuke Ishizawa, Yoshito Zamami
Summary: This study found that concomitant use of diuretics increases the risk of myocarditis in patients receiving immune checkpoint inhibitor therapy. These findings may aid in predicting the risk of myocarditis in patients receiving immune checkpoint inhibitors.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Letter
Infectious Diseases
Hideharu Hagiya, Yuka Osaki, Michio Yamamoto, Takahiro Niimura, Ko Harada, Tsukasa Higashionna, Hirofumi Hamano, Yoshito Zamami, Shiro Hinotsu, Toshihiro Koyama
JOURNAL OF INFECTION
(2023)
Article
Medicine, Research & Experimental
Toshihiko Yoshioka, Mitsuhiro Goda, Masaya Kanda, Sayuri Itobayashi, Yugo Sugimoto, Yuki Izawa-Ishizawa, Kenta Yagi, Fuka Aizawa, Koji Miyata, Takahiro Niimura, Hirofumi Hamano, Takumi Sakurada, Yoshito Zamami, Keisuke Ishizawa
Summary: This study aimed to elucidate the mechanism underlying the prophylactic effect of valproic acid on cisplatin-induced kidney injury. Results showed that combination treatment of valproic acid with cisplatin significantly improved renal function and tubular damage scores in a mouse model. Valproic acid also suppressed cisplatin-induced decrease in cell viability in HK2 cells.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE
(2023)
Article
Pharmacology & Pharmacy
Mami Neishi, Hirofumi Hamano, Takahiro Niimura, Masaya Denda, Kenta Yagi, Koji Miyata, Tsung-Jen Lin, Tsukasa Higashionna, Mitsuhiro Goda, Yoshito Zamami, Keisuke Ishizawa, Hideki Nawa
Summary: This study aimed to evaluate whether the s(-) form of esomeprazole has an improved safety profile compared with its racemic form omeprazole when combined with frequently used concomitant medications. The results showed that esomeprazole had beneficial characteristics of being less sensitive to CYP when combined with cilostazol and prasugrel. However, certain adverse event signals were detected when combined with cilostazol and clopidogrel, suggesting a potential for complications.
TOXICOLOGY AND APPLIED PHARMACOLOGY
(2023)
Article
Respiratory System
Takeshi Imakura, Seidai Sato, Kazuya Koyama, Hirohisa Ogawa, Takahiro Niimura, Kojin Murakami, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa, Yasuhiko Nishioka
Summary: This study used a systematic computational approach to identify a potential drug for the treatment of pulmonary fibrosis. The findings suggest that inhibiting a protein called PLK1 may be an effective therapeutic approach for pulmonary fibrosis without affecting lung epithelial cells. The study highlights the importance of wet-lab validation in drug discovery.
RESPIRATORY RESEARCH
(2023)
Article
Medicine, Research & Experimental
Kenta Yagi, Akinori Maruo, Shunsuke Ishida, Fuka Aizawa, Soichiro Ushio, Satoshi Sakaguchi, Makoto Kajizono, Takahiro Niimura, Mitsuhiro Goda, Hirofumi Hamano, Yuki Izawa-Ishizawa, Yoshito Zamami, Keisuke Ishizawa
Summary: This study investigated whether the use of proton pump inhibitors (PPIs) or vonoprazan affected the duration of bevacizumab treatment in patients with cancer. The results showed that for cancer types other than colorectal cancer, the duration of treatment was significantly longer in the vonoprazan group than in the PPI group. However, for colorectal cancer, the duration of bevacizumab treatment was 147 days longer in the PPI group than in the vonoprazan group. Selecting appropriate gastric acid secretion inhibitors may improve the therapeutic efficacy of anti-VEGF drugs.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
